SHANGHAI HENLIUS BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.6 HKD | -0.60% |
|
+1.59% | +19.42% |
| 05-01 | Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1 | MT |
| 04-26 | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
ETFs positioned on Shanghai Henlius Biotech, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.01% | 7 M€ | -.--% | - |
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Companyâs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Sector
Pharmaceuticals
Calendar
2024-05-20
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.38
CNY
Average target price
16.39
CNY
Spread / Average Target
+6.56%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +19.42% | 1.16B | |
| -3.79% | 87.06B | |
| +1.45% | 40.25B | |
| -15.86% | 31.09B | |
| +52.66% | 24.74B | |
| -14.47% | 15.91B | |
| -9.12% | 11.96B | |
| -14.38% | 11.92B | |
| -42.56% | 11.61B | |
| +4.87% | 8.73B |
- Stock Market
- Equities
- 2696 Stock
- Funds and ETFs Shanghai Henlius Biotech, Inc.
